21.60

5.01% -1.14

Pre-market: 22.06 0.46 +2.13%

Beam Therapeutics Inc (BEAM)

Overview News Price History Option Chain Why BEAM Down? Discussions Forecast

Beam Therapeutics Inc stock is currently priced at $21.60, with a 24-hour trading volume of 1.54M. It has seen a -5.01% decreased in the last 24 hours and a -35.89% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $23.07 pivot point. If it approaches the $21.08 support level, significant changes may occur.

Previous Close:

$22.74

Open:

$22

24h Volume:

1.54M

Market Cap:

$1.78B

Revenue:

$377.71M

Net Income/Loss:

$-132.53M

P/E Ratio:

-4.7894

EPS:

-4.51

Net Cash Flow:

$-182.93M

1W Performance:

-11.15%

1M Performance:

-35.89%

6M Performance:

+11.69%

1Y Performance:

-29.04%

1D Range:

$20.84

$22.55

52W Range:

$16.95

$49.50

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name

Beam Therapeutics Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

857 327 8775

Address

26 Landsdowne Street, 2nd Floor, Cambridge, MA

Employee

Twitter

Next Earnings Date

2024-05-08

Latest SEC Filings

BEAM's Discussions on Twitter

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Dec-08-23	Downgrade	Jefferies	Buy → Hold
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Dec-13-22	Initiated	Citigroup	Buy
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Apr-28-22	Initiated	Credit Suisse	Neutral
Jan-05-22	Initiated	Guggenheim	Buy
Oct-19-21	Initiated	SVB Leerink	Outperform
Sep-24-21	Resumed	Stifel	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight
Feb-16-21	Initiated	Wells Fargo	Overweight
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-21	Initiated	Stifel	Hold
Aug-05-20	Initiated	William Blair	Outperform
Mar-02-20	Initiated	Barclays	Overweight
Mar-02-20	Initiated	JP Morgan	Overweight
Mar-02-20	Initiated	Jefferies	Buy
Mar-02-20	Initiated	Wedbush	Outperform

View All

Beam Therapeutics Inc Stock (BEAM) Latest News

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

GlobeNewswire Inc.

Navigating 4 Analyst Ratings For Beam Therapeutics

Benzinga

Beam Therapeutics Inc Stock (BEAM) Financials Data

Beam Therapeutics Inc (BEAM) Revenue 2024

BEAM reported a revenue (TTM) of $377.71 million for the quarter ending December 31, 2023, a +520.01% rise year-over-year.

Beam Therapeutics Inc (BEAM) Net Income 2024

BEAM net income (TTM) was -$132.53 million for the quarter ending December 31, 2023, a +54.16% increase year-over-year.

Beam Therapeutics Inc (BEAM) Cash Flow 2024

BEAM recorded a free cash flow (TTM) of -$182.93 million for the quarter ending December 31, 2023, a -592.28% decrease year-over-year.

Beam Therapeutics Inc (BEAM) Earnings per Share 2024

BEAM earnings per share (TTM) was -$1.90 for the quarter ending December 31, 2023, a +54.00% growth year-over-year.

Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.